Terms: = Breast cancer AND ER, estrogen receptor AND Treatment
12546 results:
1. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
2. H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer.
Xiao CK; Ren Y; Chen Q; Yang Y; Tang L; Xu L; Ren Z
Epigenetics; 2024 Dec; 19(1):2343593. PubMed ID: 38643489
[TBL] [Abstract] [Full Text] [Related]
3. Postpartum breast cancer and Survival in Women With Germline BRCA Pathogenic Variants.
Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ
JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936
[TBL] [Abstract] [Full Text] [Related]
4. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
5. Active substance and mechanisms of Actinidia chinensis Planch for the treatment of breast cancer was explored based on network pharmacology and in silico study.
Xu Y; Yang J; Han X; Gan C; Wei X
Medicine (Baltimore); 2024 Apr; 103(15):e37829. PubMed ID: 38608062
[TBL] [Abstract] [Full Text] [Related]
6. Significance of estrogen/Progesterone receptor Expression in Metaplastic breast Carcinoma.
Hashmi AA; Mallick BA; Rashid K; Malik UA; Zia S; Zia F; Irfan M
Dis Markers; 2024; 2024():2540356. PubMed ID: 38601434
[TBL] [Abstract] [Full Text] [Related]
7. Design and methods of the mobile assessment of cognition, environment, and sleep (MACES) feasibility study in newly diagnosed breast cancer patients.
Derbes R; Hakun J; Elbich D; Master L; Berenbaum S; Huang X; Buxton OM; Chang AM; Truica CI; Sturgeon KM
Sci Rep; 2024 Apr; 14(1):8338. PubMed ID: 38594369
[TBL] [Abstract] [Full Text] [Related]
8. Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.
Bartoloni S; Pescatori S; Bianchi F; Cipolletti M; Acconcia F
Sci Rep; 2024 Apr; 14(1):8200. PubMed ID: 38589728
[TBL] [Abstract] [Full Text] [Related]
9. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer.
Xiong S; Song K; Xiang H; Luo G
Eur J Med Chem; 2024 Apr; 270():116393. PubMed ID: 38588626
[TBL] [Abstract] [Full Text] [Related]
10. Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit.
Engström T; Ekholm M; Fernö M; Lundgren C; Nordenskjöld B; Stål O; Bendahl PO; Tutzauer J; Rydén L
Acta Oncol; 2024 Apr; 63():125-136. PubMed ID: 38587062
[TBL] [Abstract] [Full Text] [Related]
11. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.
Peng DM; Li J; Qiu JX; Zhao L
World J Surg Oncol; 2024 Apr; 22(1):88. PubMed ID: 38582875
[TBL] [Abstract] [Full Text] [Related]
12. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
[TBL] [Abstract] [Full Text] [Related]
13. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis.
Bahrin NWS; Matusin SNI; Mustapa A; Huat LZ; Perera S; Hamid MRWHA
Syst Rev; 2024 Apr; 13(1):100. PubMed ID: 38576013
[TBL] [Abstract] [Full Text] [Related]
14. Case report: Primary vulvar adenocarcinoma of mammary gland type-its genetic characteristics by focused next-generation sequencing.
Hu L; Tiesinga J
Pathol Oncol Res; 2024; 30():1611376. PubMed ID: 38572338
[TBL] [Abstract] [Full Text] [Related]
15. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
Peng J; Hong Y; Chen Q; Xu F; Zhang D; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Wang S; Yi W
Front Endocrinol (Lausanne); 2024; 15():1347762. PubMed ID: 38567311
[TBL] [Abstract] [Full Text] [Related]
16. Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.
McGrath MK; Abolhassani A; Guy L; Elshazly AM; Barrett JT; Mivechi NF; Gewirtz DA; Schoenlein PV
Front Endocrinol (Lausanne); 2024; 15():1298423. PubMed ID: 38567308
[TBL] [Abstract] [Full Text] [Related]
17. The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
Ye JH; Yu J; Huang MY; Mo YM
Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
[TBL] [Abstract] [Full Text] [Related]
18. Proliferation Patterns of MCF-7 breast cancer Cells in Lipoaspirate Conditioned Media.
Chen Y; Arbuiso S; Qin N; Vernice NA; Black GG; Brown KA; Otterburn D
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S207-S209. PubMed ID: 38556675
[TBL] [Abstract] [Full Text] [Related]
19. estrogen receptor regulation of the immune microenvironment in breast cancer.
McGuinness C; Britt KL
J Steroid Biochem Mol Biol; 2024 Jun; 240():106517. PubMed ID: 38555985
[TBL] [Abstract] [Full Text] [Related]
20. Potential Value of HSP90α in Prognosis of Triple-Negative breast cancer.
Wang HF; Chen Y; Cao B; Pei J
Med Sci Monit; 2024 Mar; 30():e943049. PubMed ID: 38553816
[TBL] [Abstract] [Full Text] [Related]
[Next]
